Effectiveness of a group B outer membrane vesicle meningococcal vaccine against gonorrhoea in New Zealand: a retrospective case-control study

@article{PetousisHarris2017EffectivenessOA,
  title={Effectiveness of a group B outer membrane vesicle meningococcal vaccine against gonorrhoea in New Zealand: a retrospective case-control study},
  author={H. Petousis-Harris and J. Paynter and J. Morgan and P. Saxton and Barbara McArdle and F. Goodyear-Smith and S. Black},
  journal={The Lancet},
  year={2017},
  volume={390},
  pages={1603-1610}
}
BACKGROUND Gonorrhoea is a major global public health problem that is exacerbated by drug resistance. Effective vaccine development has been unsuccessful, but surveillance data suggest that outer membrane vesicle meningococcal group B vaccines affect the incidence of gonorrhoea. We assessed vaccine effectiveness of the outer membrane vesicle meningococcal B vaccine (MeNZB) against gonorrhoea in young adults aged 15-30 years in New Zealand. METHODS We did a retrospective case-control study of… Expand
Effectiveness of a Group B Outer Membrane Vesicle Meningococcal Vaccine in Preventing Hospitalization from Gonorrhea in New Zealand: A Retrospective Cohort Study
TLDR
The data suggests vaccination with MeNZB™ significantly reduced the rate of hospitalization from gonorrhea, and supports prior research indicating possible cross protection of this vaccine against Gonorrhea acquisition and disease in the outpatient setting. Expand
The serogroup B meningococcal outer membrane vesicle-based vaccine 4CMenB induces cross-species protection against Neisseria gonorrhoeae
TLDR
It is found that immunization with the licensed Nm OMV-based vaccine 4CMenB (Bexsero) significantly accelerated clearance and reduced the Ng bacterial burden compared to administration of alum or PBS, and implicate several Ng surface antigens as potentially protective targets. Expand
A meningococcal B vaccine induces cross-protection against gonorrhea
TLDR
There is evidence that VA-MENGOC-BC could induce a moderate protection against gonorrhea, and data clearly show a decline in the incidence of Gonorrhea following massive vaccination, in contrast with other sexually transmitted diseases. Expand
The serogroup B meningococcal outer membrane vesicle-based vaccine 4CMenB induces cross-species protection against Neisseria gonorrhoeae
TLDR
Experimental evidence is provided by demonstrating that a licensed, modified version of this Nm OMV-based vaccine accelerates clearance of Ng in a mouse infection model, confirming the possibility cross-species protection and validating the murine infection model as a relevant experimental system for investigating mechanisms of vaccine-mediated protection against gonorrhea. Expand
Exploitation of Neisseria meningitidis Group B OMV Vaccines Against N. gonorrhoeae to Inform the Development and Deployment of Effective Gonorrhea Vaccines
TLDR
Direct and indirect evidence is presented that a vaccine to control gonorrhea is not only possible, but may already exist and modeling supports that even a moderately efficacious vaccine could make a significant impact in disease prevalence. Expand
Genetic Similarity of Gonococcal Homologs to Meningococcal Outer Membrane Proteins of Serogroup B Vaccine
TLDR
A set of OMPs that may contribute to the previously observed cross-protection and provide potential antigen targets to guide the next steps in gonorrhea vaccine development are reported. Expand
First real world evidence of meningococcal group B vaccine, 4CMenB, protection against meningococcal group W disease; prospective enhanced national surveillance, England.
  • S. Ladhani, H. Campbell, +7 authors M. Ramsay
  • Medicine
  • Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 2020
TLDR
The results provide the first real-world evidence of the direct protection afforded by 4CMenB against MenW:cc11 disease and have the potential to provide some protection against all meningococcal serogroups. Expand
Impact of meningococcal group B OMV vaccines, beyond their brief
TLDR
Given the heterologous effect against diverse strains of the meningococcus observed in older children and adults, and recent evidence to suggest moderate protection against gonorrhoea, there may be a role for these vaccines in programmes targeting adolescents and groups high at risk for bothMeningococcal disease and gonor rhoea. Expand
The impact of vaccination on Neisseria gonorrhoeae antimicrobial resistance and prevalence in men who have sex with men: a mathematical modelling study
TLDR
A vaccine that has limited efficacy for the prevention of gonorrhoea could delay AMR development in MSM, providing time for developing new antimicrobials and more efficacious vaccines. Expand
Meningococcal Group B Vaccine For The Prevention Of Invasive Meningococcal Disease Caused By Neisseria meningitidis Serogroup B
TLDR
Two protein-based vaccines, namely 4CMenB (Bexsero®) and rLP2086 (Trumenba®) are currently licensed for use in different countries against MenB disease and should be considered for prevention and public health control of the disease. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 45 REFERENCES
Ecologic Study of Meningococcal B Vaccine and Neisseria gonorrhoeae Infection, Norway
TLDR
Associations between MenB vaccine coverage during 1988–1992 and national gonorrhea rates for persons >16 years of age during 1993–2008 in Norway are examined. Expand
Vaccines against meningococcal serogroup B disease containing outer membrane vesicles (OMV)
TLDR
The public health intervention in New Zealand (between 2004–2008) when MeNZB was used to control a clonal MenB epidemic provided a number of new insights regarding international and public-private collaboration, vaccine safety surveillance, vaccine effectiveness estimates and communication to the public. Expand
Neisseria gonorrhoeae Antimicrobial Susceptibility Surveillance - The Gonococcal Isolate Surveillance Project, 27 Sites, United States, 2014.
TLDR
This is the first report to present comprehensive surveillance data from GISP and summarize gonococcal susceptibility over time, as well as underscore the history and public health implications of emerging cephalosporin resistance. Expand
Efficacy trial of a parenteral gonococcal pilus vaccine in men.
TLDR
This gonococcal pilus vaccine composed of a single pilus type failed to protect men against Gonococcal urethritis and local antibodies (semen) against homologous and heterologous strains were also elicited (ELISA). Expand
Novel meningococcal 4CMenB vaccine antigens – prevalence and polymorphisms of the encoding genes in Neisseria gonorrhoeae
TLDR
The absence of NadA, lack of universal expression of fHbp and NHBA and the uncertainty regarding the surface exposure of f Hbp as well as the function of NHBA in N. gonorrhoeae will likely limit the use of the identical 4CMenB antigens in a gonococcal vaccine. Expand
Emerging experience with meningococcal serogroup B protein vaccines
TLDR
The immunogenicity and acceptable safety profile of 4CMenB and rLP2086 has been demonstrated in clinical trials, and the potential for MenB vaccines to prevent infection by other serogroups appears promising. Expand
Effectiveness of a vaccination programme for an epidemic of meningococcal B in New Zealand.
TLDR
The MeNZB vaccine was effective against the New Zealand epidemic strain of meningococcal B disease and there is evidence for some cross-protection of Me NZB against non-epidemic strains. Expand
The potential impact of vaccination on the prevalence of gonorrhea
TLDR
It is concluded that a vaccine of moderate efficacy and duration could have a substantive impact on gonococcal prevalence, and disease sequelae, if coverage is high and protection lasts over the highest risk period among young people. Expand
Vaccines against gonorrhea: current status and future challenges.
TLDR
Mechanisms by which Neisseria gonorrhoeae avoids inducing a protective adaptive response are being elucidated using human cells and the mouse model, which suggests Th1-inducing adjuvants may be key in vaccine-induced protection. Expand
Vaccines for Gonorrhea: Can We Rise to the Challenge?
TLDR
The state of the field is discussed, including unpublished data regarding efficacy in the mouse model of either viral replicon particle (VRP) vaccines, or outer membrane vesicle (OMV) vaccines; the OMV vaccines failed, despite excellent serum and mucosal antibody responses. Expand
...
1
2
3
4
5
...